| Literature DB >> 30234071 |
Hadj Slimane Touria1, Senouci Kheira1, Midoun Nori2, Bouchetara Assia3, Laradj Amel3, Bittar Fadi4.
Abstract
Epidemiological situation of infantile visceral leishmaniasis (IVL), which is a public health problem in Algeria, is almost unknown in the cities of Western part of the country. The aim of this study was to analyze the epidemiological, clinical, biological, therapeutic, and evolutionary aspects of IVL in Western Algeria, to evaluate the performance of the immunochromatography as a rapid diagnostic test of the disease, and to propose a diagnosis approach by real-time polymerase chain reaction (RT-PCR) assay from the serum. This prospective study was performed on 63 suspicious cases of visceral leishmaniasis collected from the infectious diseases department at the Pediatric Hospital of Oran from January 2012 to July 2017. For each patient, the epidemiological parameters, and the clinical and biological data were collected. Bone marrow and blood samples were drawn from all cases. Bone marrow was performed to research amastigote forms of Leishmania and to identify the species by PCR-sequencing. Blood samples were used to detect anti-Leishmania antibodies as well as parasite DNA. Patients from the Western regions were mostly from rural areas. Sensitivity of RT-PCR from the bone marrow and from serum was 95.45% and 94.44%, respectively. The immunochromatography allowed the disease's diagnosis for 11 cases whose myelogram did not confirm the presence of the amastigote forms of Leishmania. Immunochromatography was revealed to be a good technique for disease diagnosis regarding the strongly evocative clinical signs. The results also suggest the interest of the RT-PCR assay from patient serum as a non-invasive sample, in the detection of parasite DNA.Entities:
Keywords: Imunochromatography; Leishmania infantum; RT-PCR; bone marrow; sequencing; serum
Year: 2018 PMID: 30234071 PMCID: PMC6134421 DOI: 10.22088/IJMCM.BUMS.7.1.32
Source DB: PubMed Journal: Int J Mol Cell Med ISSN: 2251-9637
Fig. 1Distribution of cases according to the state of provenance
Hospitalization motifs of patients
|
|
|
|
|---|---|---|
| Febrile hepatosplenomegaly | 13 | 33,33 |
| Fever | 11 | 28, 2 |
| Febrile splenomegaly | 8 | 20,51 |
| Febrile splenomegaly and Pancytopenia | 3 | 7,69 |
| Pancytopenia | 1 | 2,56 |
| Fever and Pancytopenia | 1 | 2,56 |
| Bicytopenia | 1 | 2,56 |
| Febrile hepatosplenomegaly and bicytopenia | 1 | 2,56 |
| Total | 39 | 100 |
Fig. 2Distribution of cases according to clinical signs suggestive of the VL. HPMG : hepatomegaly; SPMG: splenomegaly
Fig. 3Distribution of cases according to the biological signs. SR: Increased sedimentation rate
Other clinical Signs
|
|
|
|
|---|---|---|
| Anorexia | 13 | 33,33 |
| Asthenia | 14 | 35,90 |
| Cough | 10 | 25,64 |
| Altered general status | 7 | 17,95 |
| Vomiting | 6 | 15,38 |
| Malnutrition | 6 | 15,38 |
| Epistaxis | 6 | 15,38 |
| Edema | 4 | 10,26 |
| Oral candidiasis | 5 | 12,82 |
| Skin Lesions | 3 | 7,69 |
| Slimming | 4 | 10,26 |
| Diarrhea | 1 | 2,56 |
| Dehydration | 2 | 5,13 |
| Peri-rectum abscess | 2 | 5,13 |
| Cervical adenopathy | 2 | 5,13 |
Biological parameters in VL-MAS cases
| Biological parameters |
|
|
|
|
|---|---|---|---|---|
| Leukocytes (4 000-10 000/mm3) | 1230 | 2640 | 2900 | 3250 |
| Hemoglobin (12-18g/dl) | 4,7 | 4,6 | 3,4 | 3,4 |
| Platelets (150 000-400 000/mm3) | 37 000 | 1100 | 6000 | 9000 |
| Ferritin (20-300µg/L) |
| NR |
|
|
| Triglycerides (<1,5nmol/L) |
|
|
|
|
| C-reactive protein (<10mg/L) | 87,39 | 60 | >60 | 36 |
| Fibrinogen (2-4g/L) | 3,37 |
| 3,74 |
|
NR: Not realized
Fig. 4Leishmania amastigote forms. A: intracellular and B: extracellular forms observed under optical microscope (x 1000)
Fig. 5Phylogenetic tree of the species. Phylogenetic tree was drawn based on sequences of the ITS1 (500 pb), ITS2 (400 bp), and Cytb (800 bp) amplified from bone marrow samples of prospective cases
Rate of clinical signs appearance of the VL according to some literature studies
| Studies | SPMG | Fever | Triad | HPMG | Paleness |
|---|---|---|---|---|---|
| (Oran, Algeria, 1st study) (n=14) ( | 92,85% | 100% | - | 85,71% | - |
| (Fes, Morocco) (n=209) ( | 97.66% | 94.5% | - | 47.36% | 50% |
| (Rabat, Morocco) (n=93) ( | 98,9% | 92,4% | 76,3% | 48,4% | - |
| (Oran, Algeria, 2nd study) (n=40) ( | 90% | 87.5% | 47.5% | 42.5% | 60% |
| (Kairouan, Tunisia) (n=240) ( | 97,9% | 79,9% | - | 47,3% | - |
| Our study (n=39) | 97,44% | 97,44% | 71,79% | 64,10% | 74,36% |
SPMG: splenomegaly; HPMG: hepatomegaly.
Summary of the bibliographic data
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Italia ( | 100% | 100% | - | - | - | - | 11 |
| Bresilia (1st study) ( | 85.7% | 82% | - | - | - | - | 21 |
| Nepal (1st study) ( | 97% | 71% | - | - | - | - | 139 |
| Nepal (2nd study) ( | 100% | 100% | - | - | - | - | 14 |
| India ( | 99% | 89% | - | - | - | - | 150 |
| French ( | 97% | 98% | 89% | 94% | - | - | 34 |
| Bresil (2nd study) (35) | 93% | 97% | 98% | 89% | - | - | 332 |
| Tunisia (36) | 87.1% | 94.4% | 96.2% | 81.9% | - | - | 574 |
| Present study | 92,3% | 100% | 100% | 88,9% | 0,92 | 1 | 100 |
Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value; J: Youden index; Q: Yule's coefficient.